Graybug Vision

Graybug Vision is an early stage pharmaceutical company committed to developing therapies that may transform care for ocular diseases including wet age-related macular degeneration (AMD) and glaucoma. Graybug Vision’s technology was first developed at Johns Hopkins University and has been spun out into a startup venture. Graybug Vision is developing ophthalmology products enabling potentially twice per year dosing using its novel injectable depot technology.